In vitro activity of sparfloxacin (CI-978, AT-4140, and PD 131501)
| Autor: | Carl L. Heifetz, Steven L. Yoder, Gregory E. Roland, Gail B. Mailloux, Michael A. Cohen, M D Huband |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Microbiology (medical)
biology medicine.drug_class General Medicine biochemical phenomena metabolism and nutrition Quinolone biology.organism_classification Enterococcus faecalis Microbiology Minimum inhibitory concentration Infectious Diseases Sparfloxacin Branhamella medicine Ofloxacin Moraxella Antibacterial agent medicine.drug |
| Zdroj: | Diagnostic Microbiology and Infectious Disease. 14:403-415 |
| ISSN: | 0732-8893 |
| DOI: | 10.1016/0732-8893(91)90067-p |
| Popis: | Sparfloxacin (CI-978, AT-4140 and PD 131501) is a new antimicrobial agent of the piperazinyl quinolone class. Relative to other quinolones, it is a potent antistaphylococcal and antistreptococcal drug in vitro: The microbroth 90% minimum inhibitory concentration (MIC 90 ) (in μg/ml) was 0.25 vs 26 methicillin-resistant and -sensitive coagulase-positive and - negative staphylococci and 20 Streptococcus pneumoniae; 0.5 vs 20 strains each of S. pyogenes , S. agalactiae , and Enterococcus faecalis . The data indicate sparfloxacin to be generally superior to ciprofloxacin, ofloxacin, oxacillin, cefazolin, doxycycline, amikacin, and vancomycin against these Gram-positive bacterial groups. Additional MIC 90 s were determined for Haemophilus influenzae, Moraxella (Branhamella) catarrhalis , and Neisseria gonorrhoeae (≤ 0.03); Enterobacteriaceae (0.5); and Listeria monocytogenes (1). Activity was generally unchanged with light, 50% human serum, aerobic-anaerobic atmosphere, 5% sodium cholate, cation supplementation, and 100-fold increased or decreased inoculum; as with other quinolones, potency was measurably diminished with decreasing pH (pH ≤ 6.0) and in 100% urine. Naturally occurring resistant mutants occurred at frequencies of 10 −8 or lower. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|